Nyxoah Announces Pricing of Offering

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Pricing of Offering

Mont-Saint-Guibert, Belgium – May 23, 2024, 3:50 pm CET / 9:50 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 5,374,755 of its ordinary shares at an offering price of $9.25 (EUR 8.54) per share, before underwriting discounts and commissions. All of the ordinary shares are being offered by Nyxoah and there are no selling stockholders participating in the offering. In addition, Nyxoah has granted the underwriters a 30-day option to purchase up to an additional 806,213 ordinary shares at the offering price, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nyxoah, are expected to be approximately $50 million (EUR 46.2 million), excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close May 28, 2024, subject to the satisfaction of customary closing conditions.

Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Degroof Petercam is acting as a co-manager.

The public offering in the United States is being made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-268955) that was filed by Nyxoah with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on January 6, 2023. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained by contacting: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022; email: prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Additional information
The following information is provided pursuant to Article 7:97 of the Belgian Companies and Associations Code. Prior to the launch of the offering, Robert Taub, who is the chairman of the board of directors, had expressed an interest to participate in the offering and purchase (either directly or indirectly through entities controlled/managed by him or otherwise) offered shares, it being understood that the number of offered shares allocated to Robert Taub (if any) and the applicable price would depend on the outcome of the offering process.

As Robert Taub qualifies as a related party of the Company, the board of directors applied the related parties procedure of Article 7:97 of the Belgian Companies and Associations Code in connection with the potential participation of Robert Taub (either directly or indirectly through entities controlled/managed by him or otherwise) to the offering. Within the context of the aforementioned procedure, prior to resolving on the offering, a committee of three independent directors of the Company (the “Committee”) issued an advice to the board of directors in which the Committee assessed the participation of Robert Taub in the offering. In its advice to the board of directors, the Committee concluded the following: “Based on the information provided, the Committee considers that the proposed transaction is in line with the strategy pursued by the Company, will be done on market terms, and is unlikely to lead to disadvantages for the Company and its shareholders (in terms of dilution) that are not sufficiently compensated by the advantages that the transaction offers the Company”.

When approving the offering, the Company’s board of directors did not deviate from the Committee’s advice. The Company’s statutory auditor’s assessment of the Committee’s advice and the minutes of the meeting of the Company’s board of directors, is as follows: “Based on our limited review performed in accordance with ISRE 2410 “ Review of interim financial information performed by the independent auditor of the entity” and the applicable standards of the “Institut des Réviseurs d’Entreprises/Instituut der Bedrijfsrevisoren”, nothing has come to our attention that causes us to believe that the financial and accounting data contained in the minutes of the board of directors’ meeting of May 22, 2024 and in the advice of the committee of independent directors in accordance with article 7:97 of the Companies and Associations Code would contain material inconsistencies with the information available to us in the course of our engagement. However, we do not express an opinion on the value of the transaction or on the appropriateness of the decision of the board of directors”.

Important Information
No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of the Belgian Act of 11 July 2018 on the public offering of securities and the admission of securities to be traded on a regulated market, will not be eligible to participate in the offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, (i) any person who is a “qualified investor” as defined in Regulation (EU) 2017/1129 (the “EU Prospectus Regulation”), or (ii) fewer than 150 natural or legal persons, per each member state of the European Economic Area, other than “qualified investors” (as defined in the EU Prospectus Regulation) who acquire ordinary shares for a total consideration of at least €100,000 per investor.

In the United Kingdom, the transaction to which this press release relates will only be available to, and will only be engaged in with, persons who are “qualified investors” (as defined in the UK Prospectus Regulation being the UK version of Regulation (EU) No 2017/1129 as amended by The Prospectus (Amendment etc.) (EU Exit) Regulations 2019, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.) who also (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), and/or (ii) are “high net worth companies” (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2) (a) to (d) of the Order (any such person being referred to as a “Relevant Person”). Any person who is not a Relevant Person should not take any action on the basis of this announcement and should not act or rely on it.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-Looking Statements

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements may be identified by words such as “expects,” “potential,” “could,” or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include express or implied statements relating to, among other things, Nyxoah’s current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies; and statements relating to the offering, including the expected closing, the anticipated proceeds from the offering and the use thereof. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Nyxoah’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation, risks relating to market conditions and the Company’s inability, or the inability of the underwriters, to satisfy the conditions for the closing of the offering. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Nyxoah include those identified under the heading “Risk Factors” in Nyxoah’s most recent Annual Report on Form 20-F filed with the SEC, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Nyxoah’s views as of the date hereof, and Nyxoah does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

Attachment

GlobeNewswire Distribution ID 1000952500

Gov. Holcomb elevates Indiana to the world’s stage at Global Economic Summit

Governor, IEDC welcome industry, government and academic leaders from the global market to tackle most pressing worldwide issues

INDIANAPOLIS, May 23, 2024 (GLOBE NEWSWIRE) — Governor Eric J. Holcomb kicked off the second Indiana Global Economic Summit today, welcoming international delegations from more than 30 countries and territories, business executives, academic and government leaders. The summit, hosted today through May 26, will convene thought leaders from around the globe to discuss the future of AI, national security, integrated health, global sports and more.

Gov. Holcomb delivered this morning’s opening address at the Indianapolis Convention Center. At the conclusion of the Summit, Gov. Holcomb and Indiana Secretary of Commerce David Rosenberg will host dignitaries and business leaders at the Indianapolis 500, which will shine a global spotlight on Indiana and its innovation in motorsports.

“This week, we’ve brought the world to Indiana, and I couldn’t be more excited for these next few days of important discussions,” said Gov. Holcomb. “The work we do this week at the second Indiana Global Economic Summit tees up years of productivity ahead. Together, with our home and away partners, we’re building the future economy and creating a better, more prosperous life for Hoosiers and all that we do business with.”

Roughly 800 people including 41 diplomatic delegations from 31 countries and territories are expected to participate.

Global leaders gathering at the Summit will discuss topics such as sustaining a creative economy in an AI future, navigating global trade winds, building supply chain resiliency in critical industries, and harnessing defense strategy and innovation in the face of global conflict. They will also conduct business-to-business matchmaking and discuss ways to address global challenges such as economic security and workforce.

Speakers include:

  • Dave Ricks, Chair and CEO, Eli Lilly & Company
  • Micael Johansson, President and CEO, Saab AB
  • Ben Townsend, Global Head of Infrastructure & Sustainability, Google
  • Kiva Allgood, Head of Center for Advanced Manufacturing and Supply Chain, World Economic Forum
  • Oksana Markarova, Ambassador of Ukraine to the U.S., Embassy of Ukraine in the U.S.
  • Mel Raines, President and COO, Pacers Sports and Entertainment
  • Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, U.S. Department of Energy

Additional featured speakers are listed here.

International delegations participating in the Summit include national and subnational delegations from the following countries and territories:

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Croatia
  • Denmark
  • France
  • Germany
  • Greece
  • Hungary
  • India
  • Ireland
  • Israel
  • Italy
  • Japan
  • Lithuania
  • Malaysia
  • Mexico
  • Mongolia
  • Netherlands
  • Pakistan
  • Peru
  • Saudi Arabia
  • Slovakia
  • South Korea
  • Switzerland
  • Taiwan
  • Turkey
  • Ukraine
  • United Kingdom

“Building meaningful partnerships is what Indiana does best, and we are thrilled to welcome global leaders to Indiana this week as we celebrate our historic economic momentum and explore new ways to build our economy with like-minded partners,” said Sec. Rosenberg. “The Summit provides an opportunity for us to reach across borders and truly curate an intentional economy that will create lasting change for Indiana.”

This year’s summit comes on the heels of the first-ever Indiana Global Economic Summit hosted in May 2022, which convened more than 900 registrants from 30 countries and territories. 98% of 2022 survey respondents said they were more inclined after attending the summit to view Indiana as a leader in developing future innovations and in driving the economy of the future. More information on the Summit is available here.

About the Indiana Global Economic Summit Hosted by Governor Eric J. Holcomb and the Indiana Economic Development Corporation, the 2024 Indiana Global Economic Summit is convening Indiana, U.S. and international decision makers to advance critical conversations, catalyze innovation and create opportunities for deeper economic and international cooperation. This event is strategically designed to connect leading voices and share global perspectives to shape next-generation innovation, industry and talent.

Attachment

Erin Murphy
Office of Governor Eric J. Holcomb
317-618-7635
emurphy2@gov.in.gov

GlobeNewswire Distribution ID 9122849

MING launches the 37.09 Bluefin, a new 600m dive watch with an internally rotating sapphire dial

MING 3709-1

Different day and night signatures

LA CHAUX-DE-FONDS, Switzerland, May 23, 2024 (GLOBE NEWSWIRE) — Today, Horologer MING releases the new 37.09 Bluefin, featuring their third-generation design language. It is their first watch with a unidirectionally-rotating, luminous sapphire timing dial that replaces a conventional dive bezel. It rides on bearings and is set by a dedicated crown. The Bluefin’s steel case is water resistant to 600m, but comfortably sized at 38×12.8mm. It is powered by a customized Sellita SW300-1 with 50 hours of power reserve and bidirectional automatic winding.

The 37.09 Bluefin continues the MING design tradition of graphically minimalist scales that are easy to read and index. A new metallisation process creates a deep blue hue on the sapphire dial, which along with the hands, is extensively treated with Super-LumiNova X1 for optimal legibility under all conditions.

MING 3709-02

Internally-rotating sapphire dial and display back

Watches will be delivered on a new moulded FKM rubber strap that is also compatible with all of MING’s previous 20mm lug watches. The natural shape of the strap matches the curvature of the average wrist, and it is also keeperless and tapered in thickness to further enhance comfort. It will be available as a standalone accessory as well.

MING 3709-03

MING 37.09 Bluefin featuring new moulded FKM rubber strap

The MING 37.09 Bluefin is priced at CHF 4,950, with 500 watches produced for 2024. They will be exclusively available at www.ming.watch from 1PM GMT on 24 May 2024, with deliveries expected to begin October 2024.

MING 37.09 Bluefin Specifications

  • Case: 316L stainless steel, 38mm diameter, 12.8mm thickness, 44.5mm interlug
  • Domed sapphire crystals with double anti-reflective coating
  • Super-LumiNova X1 markings
  • 600m water resistance
  • Sellita for MING SW300.M1 with anthracite skeletonized bridges; automatic with 50h power reserve
  • Moulded FKM rubber strap
  • 2-year warranty
  • Made in Switzerland

About MING:

Horologer MING is an independent watch brand with the goal of reviving a sense of excitement and discovery among watch enthusiasts. We are dedicated to refined aesthetics, and pushing the boundaries of materials, mechanics and engineering. This has won us many accolades including the Horological Revelation Prize at the 2019 Grand Prix d’Horlogerie de Genève. MING products are available exclusively online at www.ming.watch. Subscribe to our newsletter and follow our Instagram for the latest updates from MING.

3709-04

Super-LumiNova X1 on hands and dial for optimal legibility under all conditions

MING is an internationally registered trademark of Horologer MING SA, Switzerland.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/2bd25487-a818-4ba9-bb20-50bf483292aa

https://www.globenewswire.com/NewsRoom/AttachmentNg/8939444e-1ab6-4d69-8521-61bd8e09549b

https://www.globenewswire.com/NewsRoom/AttachmentNg/f1879a61-4acb-4f68-bf09-f8f71b299f15

https://www.globenewswire.com/NewsRoom/AttachmentNg/08ee080d-2573-4c01-a1fa-5eb720e4868f

Contact

Praneeth Rajsingh
media@ming.watch
+6019 808 0939

GlobeNewswire Distribution ID 1000952383

‫إس سي جي إنترناشونال تتعاون مع بنى المملكة لدفع ابتكارات البناء المستدام في المملكة

بانكوك، تايلاند – اتخذت شركة إس سي جي إنترناشونال (إس سي جي إنترناشونال) خطوة كبيرة في تعزيز الإشراف البيئي من خلال تحرير مذكرة تفاهم مع شركة بنى المملكة (بنى) لتقديم تقنيات البناء المتقدمة والمستدامة في المملكة العربية السعودية.  لا يقتصر هذا التعاون على إنشاء صالات عرض في المناطق الرئيسية لبيع وتوزيع مواد البناء المصنعة والمزودة بمعرفة شركة إس سي جي فحسب، بل يهدف أيضًا إلى تحقيق التوسع الاستراتيجي لشركة إس سي جي إنترناشونال في جميع أنحاء جنوب آسيا والشرق الأوسط وأفريقيا (SAMEA)، مع التركيز على دمج الممارسات المستدامة في عملياتها التجارية.

تستفيد الشراكة من تقنيات البناء الخضراء مثل الخرسانة فائقة الأداء (UHPC)، وتقنية الخرسانة الجاهزة من شركة إس سي جي، وطباعة شركة إس سي جي ثلاثية الأبعاد لتقليل التأثيرات البيئية. تُستخدم الخرسانة فائقة الأداء في إنشاء هياكل أكثر نحافة وأخف وزنًا وأكثر قوة وقادرة على التعامل مع الأحمال الثقيلة، وذلك باستخدام مواد أقل مع تعزيز الاستدامة. تعمل الخرسانة الجاهزة من شركة إس سي جي على تحسين الخلطات الخرسانية لتقليل استخدام الموارد والنفايات، كما تعمل تقنية الطباعة ثلاثية الأبعاد التي توفرها الشركة على تعزيز دقة البناء، وتقليل هدر المواد، وتقليل انبعاثات الكربون.

يقود هذه المبادرة السيد أبهيجيت داتا، العضو المنتدب لشركة إس سي جي إنترناشونال، والسيد إسلام م. رضوان، الرئيس التنفيذي لشركة بنى، حيث يلتزم كلاهما بدمج الاستدامة بشكل عميق في أطر العمل التشغيلية لديهما، بهدف تحويل مشهد البناء الإقليمي من خلال ممارسات صديقة للبيئة ومُجدية اقتصاديًا ومسؤولة اجتماعيًا.

ومن خلال هذه الجهود، تضع شركة إس سي جي إنترناشونال وشركة بنى معايير صناعية جديدة، مما يوضح كيف يمكن للشراكات الاستراتيجية أن تساهم بشكل كبير في تحقيق أهداف الاستدامة العالمية. لا تؤكد هذه المبادرة على إمكانات الابتكار الصناعي لدعم ممارسات البناء الأكثر مراعاة للبيئة فحسب، بل تسلط الضوء أيضًا على أهمية التعاون الدولي في معالجة التحديات البيئية.

قال السيد أبهيجيت داتا، رئيس الأعمال الدولية والعضو المنتدب لشركة إس سي جي إنترناشونال: “نأمل أن يعزز هذا التعاون قدرات شركة إس سي جي في مجال الابتكار وتقنيات البناء، من خلال الشراكة مع شركة بنى، وهي شركة رئيسية في مجال البناء في المملكة العربية السعودية. نأمل معًا أن نضع الأساس لمستقبل حيث ستساعد التقنيات والشراكات في تغيير طريقة تشييد المباني. علاوة على ذلك، فإننا نهدف إلى الاستفادة من قدرات شركة بنى للتعاون معنا في تايلاند ودول الآسيان. وتعد مذكرة التفاهم هذه بمثابة شهادة على التزامنا المشترك بالابتكار والتكنولوجيا المستدامة، وآمل أن يكون لدينا تعاون قوي للغاية للمضي قدمًا.

وقال السيد إسلام م. رضوان، الرئيس التنفيذي لشركة بنى المملكة: “يسعدني أن شركة بنى المملكة قد انضمت إلى شركة إس سي جي إنترناشونال. على الرغم من أن النتائج قد لا تكون مرئية على الفور، إلا أننا واثقون من أن استخدام تقنية شركة إس سي جي سيعزز قدراتنا التنافسية في سوق المملكة العربية السعودية. ولن يؤدي هذا التعاون إلى تحسين مشاريعنا فحسب، بل سيعرض أيضًا تكنولوجيا البناء الأخضر في المملكة، بما يتماشى مع رؤية المملكة 2030.

نبذة عن شركة إس سي جي إنترناشيونال

شركة إس سي جي إنترناشيونال المحدودة هي شركة تابعة لشركة سيام للأسمنت العامة المحدودة (BKK:SCC)، وهي كيان عالمي مشهور تأسس عام 1978 في بانكوك. باعتبارها شركة تجارية تحولت إلى قوة دولية، تعمل شركة إس سي جي إنترناشيونال الآن في 20 موقعًا حول العالم، وتخدم أكثر من 2,000 عميل من عملاء الشركات في أكثر من 50 دولة. بحلول عام 2022، نجحت الشركة في التحول إلى شريك دولي موثوق به في سلسلة التوريد، حيث تقدم حلولاً شاملة لتعزيز تنوع سلسلة التوريد، وتخفيف المخاطر، وفتح إمكانات الأعمال. بفضل التزامها الثابت بالاستدامة، تدعم الشركة بفعالية صناعات متنوعة وتحقق إيرادات سنوية تبلغ حوالي 1,5 مليار دولار أمريكي.

لمزيد من المعلومات، تفضل بزيارة موقعنا: www.scginternational.com

 

Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program

Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today that it has reduced the maximum amount of 6,000,000 ordinary shares available for issuance under its “at-the-market” offering (announced on December 22, 2022) by an amount of 1,569,139 ordinary shares, or share capital of EUR 269,579 (excluding issuance premium), resulting in (i) a maximum of 4,430,861 ordinary shares to be issued under its “at-the-market” offering, of which 3,662,699 ordinary shares remain available for issuance, and (ii) an increase of the authorized capital that is available to the board of directors by EUR 269,579. For further context, please refer to section 1.5.2 of the May 22, 2024 board report that is available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials > Special Reports).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements may be identified by words such as “expects,” “potential,” “could,” or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include express or implied statements relating to, among other things, Nyxoah’s current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies; and statements relating to the offering, including the expected closing, the anticipated proceeds from the offering and the use thereof. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Nyxoah’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation, risks relating to market conditions and the Company’s inability, or the inability of the underwriters, to satisfy the conditions for the closing of the offering. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Nyxoah include those identified under the heading “Risk Factors” in Nyxoah’s most recent Annual Report on Form 20-F filed with the SEC, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Nyxoah’s views as of the date hereof, and Nyxoah does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

Attachment

GlobeNewswire Distribution ID 1000952325

Nyxoah Announces Proposed Offering of Ordinary Shares

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Proposed Offering of Ordinary Shares

Mont-Saint-Guibert, Belgium – May 22, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. All of the ordinary shares are being offered by Nyxoah and there are no selling stockholders in the proposed offering. In addition, Nyxoah expects to grant the underwriters a 30-day option to purchase additional ordinary shares in an amount of up to 15% of the number of shares sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Degroof Petercam is acting as a co-manager.

The public offering in the United States will be made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-268955) that was filed by Nyxoah with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on January 6, 2023. A preliminary prospectus supplement will be filed with the SEC and the accompanying prospectus relating to and describing the terms of the offering will be and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022; email: prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Important Information
No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of the Belgian Act of 11 July 2018 on the public offering of securities and the admission of securities to be traded on a regulated market, will not be eligible to participate in the offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, (i) any person who is a “qualified investor” as defined in Regulation (EU) 2017/1129 (the “EU Prospectus Regulation”), or (ii) fewer than 150 natural or legal persons, per each member state of the European Economic Area, other than “qualified investors” (as defined in the EU Prospectus Regulation) who acquire ordinary shares for a total consideration of at least €100,000 per investor.

In the United Kingdom, the transaction to which this press release relates will only be available to, and will only be engaged in with, persons who are “qualified investors” (as defined in the UK Prospectus Regulation being the UK version of Regulation (EU) No 2017/1129 as amended by The Prospectus (Amendment etc.) (EU Exit) Regulations 2019, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.) who also (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), and/or (ii) are “high net worth companies” (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2) (a) to (d) of the Order (any such person being referred to as a “Relevant Person”). Any person who is not a Relevant Person should not take any action on the basis of this announcement and should not act or rely on it.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements may be identified by words such as “expects,” “potential,” “could,” or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include express or implied statements relating to, among other things, Nyxoah’s current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies; and statements relating to the offering, including the expected closing, the anticipated proceeds from the offering and the use thereof. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Nyxoah’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation, risks relating to market conditions and the Company’s inability, or the inability of the underwriters, to satisfy the conditions for the closing of the offering. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Nyxoah include those identified under the heading “Risk Factors” in Nyxoah’s most recent Annual Report on Form 20-F filed with the SEC, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Nyxoah’s views as of the date hereof, and Nyxoah does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer

IR@nyxoah.com

Attachment

GlobeNewswire Distribution ID 1000952322